Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist

Ali, Rouchan; Virendra, Sharma Arvind; Chawla, Pooja

doi:10.1016/j.hsr.2022.100032

Cited by 5 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tirzepatide has been approved by FDA in May 2022. Since it has revealed significant improvement in glycemic control and weight loss compared to other alternatives, currently it can now be recommended off-label for the treatment of obesity and implemented as a second-line T2DM medication, maximizing similar advantages that are reported with established GLP-1 medications ( 43 , 44 ). On this matter, The SURPASS clinical trial program’s goal in this area was to examine the effectiveness and safety of tirzepatide in T2DM patients.…”

Section: Discussionmentioning

confidence: 99%

The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials

Rohani,

Malekpour Alamdari,

Bagheri

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundDespite the fact that obesity and overweight are serious major health problems worldwide, fighting against them is also considered a challenging issue. Several interventional studies have evaluated the potential weight-reduction effect of Tirzepatide. In order to obtain a better viewpoint from them, this study aimed to comprehensively investigate the effects of subcutaneous Tirzepatide on obesity and overweight.MethodsScopus, PubMed/Medline, Web of Science, Cochrane, and Embase databases were searched using standard keywords to identify all controlled trials investigating the weight loss effects of Tirzepatide. Pooled weighted mean difference and 95% confidence intervals were achieved by random-effects model analysis for the best estimation of outcomes. The statistical heterogeneity and publication bias were determined using the Cochran’s Q test and I2 statistics and using the funnel plot and Egger’s test, respectively.ResultsTwenty three treatments arm with 7062 participants’ were included in this systematic review and meta‐regression analysis. The pooled findings showed that Tirzepatide vs placebo significantly reduced body weight (weighted mean difference (WMD): -11.34 kg, 95% confidence interval (CI): -12.79 to -9.88, P< 0.001), body mass index (BMI) (WMD: -3.11 kg/m2, 95% CI: -4.36 to -1.86, P< 0.001), and waist circumference (WC) (WMD: -7.24 cm, 95% CI -10.12 to -4.36, P< 0.001). These reductions were even greater, especially with higher doses and duration of Tirzepatide.ConclusionsTirzepatide medication had significant effects on weight management with the reduction of body weight, BMI, and WC. Administration of Tirzepatide can be considered a therapeutic strategy for overweight or obese people.

show abstract

Section: Discussionmentioning

confidence: 99%

The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials

Rohani,

Malekpour Alamdari,

Bagheri

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…The involvement of GIP at the molecular level is very similar to GLP-1. It causes an increase in cAMP which ultimately increases insulin release from pancreatic beta cells while also upregulating pro-insulin gene transcription and leading to increased insulin content within beta cells [101]. However, these effects are not observed in those with insulin-resistant conditions like type 2 diabetes [102].…”

Section: Insulinmentioning

confidence: 99%

“…This drug aids in controlling blood glucose concentrations which, by definition, are impaired in patients with type 2 diabetes [106]. Tirzepatide is given to patients with type 2 diabetes after meals to stimulate insulin during both phases of its secretion and concurrently suppresses glucagon release, decreasing blood glucose levels [101]. Tirzepatide also increases insulin sensitivity, which aids glucose transport into cells.…”

Section: Pharmacodynamics Of Tirzepatidementioning

confidence: 99%

The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome

Anala,

Saifudeen,

Ibrahim

et al. 2023

JCM

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy in women of reproductive age. The metabolic dysfunction associated with PCOS increases the probability of developing type 2 diabetes (T2D), endometrial cancer, and cardiovascular disease. Research has shown that the metabolic features of PCOS may be improved by weight loss following treatment with glucagon-like peptide-1 receptor (GLP-1R) agonists. Tirzepatide is a dual GLP-GIP (gastric inhibitory polypeptide) receptor agonist that shares a very similar mechanism of action with GLP-1R agonists, and it is hypothesized that it may be a potential contender in the treatment of PCOS. The success of GLP-1R agonists is usually hindered by their adverse gastrointestinal effects, leading to reduced compliance. The mechanism of action of Tirzepatide partly addresses this issue, as its dual receptor affinity may reduce the intensity of gastrointestinal symptoms. Tirzepatide has been licensed for the treatment of type 2 diabetes and given the metabolic issues and obesity that accompanies PCOS, it may be of value in its management for those PCOS patients who are obese with metabolic syndrome, although it may not benefit those who are of normal weight. This study reviews the current therapies for the treatment of PCOS and evaluates the potential use of Tirzepatide to address the symptoms of PCOS, including reproductive dysfunction, obesity, and insulin resistance.

show abstract

Current Status of Therapeutic Peptides for the Management of Diabetes Mellitus

Prajapati,

Rana,

Rangra

et al. 2024

Int J Pept Res Ther

View full text Add to dashboard Cite

Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist

Cited by 5 publications

References 11 publications

The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials

The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials

The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome

Current Status of Therapeutic Peptides for the Management of Diabetes Mellitus

Contact Info

Product

Resources

About